AbbVie (NYSE:ABBV) Updates Q3 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its third quarter 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 3.840-3.880 for the period, compared to the consensus estimate of 3.850. The company issued revenue guidance of $17.2 billion-$17.2 billion, compared to the consensus revenue estimate of $17.3 billion.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent research reports. Cantor Fitzgerald lifted their price target on shares of AbbVie from $240.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, July 6th. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Evercore set a $235.00 target price on shares of AbbVie in a research note on Friday, May 15th. Finally, BMO Capital Markets increased their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $269.29.

AbbVie Stock Down 1.2%

ABBV traded down $3.13 on Friday, reaching $254.28. The company had a trading volume of 2,083,611 shares, compared to its average volume of 7,003,763. AbbVie has a 1 year low of $187.62 and a 1 year high of $267.47. The stock has a market capitalization of $449.25 billion, a PE ratio of 125.28, a P/E/G ratio of 0.87 and a beta of 0.30. The stock has a 50-day moving average price of $238.39 and a 200-day moving average price of $223.86.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.60 by $0.05. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.During the same quarter last year, the business earned $2.97 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie will post 14.14 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s payout ratio is 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie exceeded expectations with adjusted EPS of $3.65 versus the $3.60 consensus, while revenue increased 10.2% year over year to $16.99 billion. Adjusted EPS rose 22.9% from the prior-year quarter. Reuters earnings report
• Positive Sentiment: The core immunology franchise remained strong: Skyrizi generated $5.505 billion and Rinvoq produced $2.525 billion, helping global immunology revenue grow 15.1%. Neuroscience revenue also climbed 20.3%, led by Vraylar and Botox Therapeutic, while Botox showed signs of recovery in the aesthetics business. Financial Post Botox recovery report
• Positive Sentiment: European regulators approved Rinvoq for severe alopecia areata in adults and adolescents, expanding the drug’s addressable market and supporting AbbVie’s post-Humira growth strategy. Rinvoq European approval
• Neutral Sentiment: AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion to strengthen its immunology pipeline. The deal could improve long-term growth, but it is expected to close in the third quarter and carries near-term integration and financing risks.
• Negative Sentiment: The company lowered its 2026 adjusted EPS guidance from $13.91–$14.11 to $13.87–$14.07, including a $0.14-per-share dilution from the Apogee transaction and additional acquired research expenses. The cut gives investors a reason to take profits despite the earnings beat. Wall Street Journal guidance report

Hedge Funds Weigh In On AbbVie

A number of hedge funds have recently modified their holdings of the business. Bank of Jackson Hole Trust increased its stake in shares of AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock worth $1,648,000 after purchasing an additional 44 shares in the last quarter. Imprint Wealth LLC lifted its stake in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares in the last quarter. one8zero8 LLC lifted its stake in AbbVie by 0.5% in the 4th quarter. one8zero8 LLC now owns 9,825 shares of the company’s stock valued at $2,245,000 after buying an additional 50 shares in the last quarter. Papamarkou Wellner Asset Management inc. grew its holdings in AbbVie by 0.5% during the 4th quarter. Papamarkou Wellner Asset Management inc. now owns 9,611 shares of the company’s stock valued at $2,196,000 after buying an additional 52 shares during the last quarter. Finally, Hoxton Planning & Management LLC grew its holdings in AbbVie by 2.8% during the 4th quarter. Hoxton Planning & Management LLC now owns 2,115 shares of the company’s stock valued at $483,000 after buying an additional 57 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.